P eople with pockets of fat hidden inside their muscles are at a higher risk of dying or being hospitalised from a heart ...

Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing kidney failure risk, disease progression, and death due to ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular ...

People with pockets of fat hidden inside their muscles are at a higher risk of dying or being hospitalised from a heart ...

Novo Nordisk (NVO) announced that the Food and Drug Administration has approved Ozempic to reduce the risk of kidney disease worsening, kidney ...

News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...